LISTING OF CLAIMS

1. (Currently Amended) A compound of formula (I):



(I)

wherein W is hydrogen, C_{1-10} alkyl, C_{3-12} cycloalkyl, C_{3-12} cycloalkylC_{1-4}alkyl-, C_{1-10} alkoxy, C_{3-12} cycloalkoxy-, C_{1-10} alkyl substituted with 1-3 halogen, C_{3-12} cycloalkyl substituted with 1-3 halogen, C_{3-12} cycloalkylC_{1-4}alkyl- substituted with 1-3 halogen, C_{1-10} alkoxy substituted with 1-3 halogen, C_{3-12} cycloalkoxy- substituted with 1-3 halogen, -$COOV_1$, -$C_{1-4}COOV_1$, -CH_2OH, -$SO_2N(V_1)_2$, hydroxyC_{1-10}alkyl-, hydroxyC_{3-10}cycloalkyl-, cyanoC_{1-10}alkyl-, cyanoC_{3-10}cycloalkyl-, -$CON(V_1)_2$, $NH_2SO_2C_{1-4}$alkyl-, NH_2SOC_{1-4}alkyl-, sulfonylaminoC_{1-10}alkyl-, diaminoalkyl-, -sulfonylC_{1-4}alkyl, a 6-membered heterocyclic ring, a 6-membered heteroaromatic ring, a 6-membered heterocyclicC_{1-4}alkyl-, a 6-membered heteroaromaticC_{1-4}alkyl-, a 6-membered aromatic ring, a 6-membered aromaticC_{1-4} alkyl-, a 5-membered heterocyclic ring optionally substituted with an oxo or thio, a 5-membered heteroaromatic ring, a 5-membered heterocyclicC_{1-4}alkyl- optionally substituted with an oxo or thio, a 5-membered heteroaromaticC_{1-4}alkyl-, -$C_{1-5}(=O)W_1$, -$C_{1-5}(=NH)W_1$, -$C_{1-5}NHC(=O)W_1$, -$C_{1-5}NHS(=O)_2W_1$, -$C_{1-5}NHS(=O)W_1$, wherein W_1 is hydrogen, C_{1-10} alkyl, C_{3-12} cycloalkyl, C_{1-10} alkoxy, C_{3-12}

cycloalkoxy, -CH_2OH, amino, C_{1-4}alkylamino-, or diC_{1-4}alkylamino-, or a 5-membered heteroaromatic ring optionally substituted with 1-3 lower alkyl;

wherein each V_1 is independently selected from H, C_{1-6} alkyl, C_{3-6} cycloalkyl, benzyl or phenyl;

Q is a C_{1-8} alkyl, 5-8 membered cycloalkyl, 5-8 membered heterocyclic or a 6 membered ~~aromatic or~~ heteroaromatic group;

n is an integer from 0 to 3;

A, B and C are independently hydrogen, C_{1-10} alkyl, C_{3-12} cycloalkyl, C_{1-10} alkoxy, C_{3-12} cycloalkoxy, -CH_2OH, -$NHSO_2$, hydroxyC_{1-10}alkyl-, aminocarbonyl-, C_{1-4}alkylaminocarbonyl-, diC_{1-4}alkylaminocarbonyl-, acylamino-, acylaminoalkyl-, amide, sulfonylaminoC_{1-10}alkyl-, or A-B can together form a C_{2-6} bridge, or B-C can together form a C_{3-7} bridge, or A-C can together form a C_{1-5} bridge;

Z is selected from the group consisting of a bond, straight or branched C_{1-6} alkylene, -NH-, -CH_2O-, -CH_2NH-, -$CH_2N(CH_3)$-, -$NHCH_2$-, -CH_2CONH-, -$NHCH_2CO$-, -CH_2CO-, -$COCH_2$-, -CH_2COCH_2-, -$CH(CH_3)$-, -CH=, -O- and -HC=CH-, wherein the carbon and/or nitrogen atoms are unsubstituted or substituted with one or more lower alkyl, hydroxy, halo or alkoxy group;

R_1 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{3-12}cycloalkyl, C_{2-10}alkenyl, amino, C_{1-10}alkylamino-, C_{3-12}cycloalkylamino-, -$COOV_1$, -$C_{1-4}COOV_1$, cyano, cyanoC_{1-10}alkyl-, cyanoC_{3-10}cycloalkyl-, NH_2SO_2-, $NH_2SO_2C_{1-4}$alkyl-, NH_2SOC_{1-4}alkyl-, aminocarbonyl-, C_{1-4}alkylaminocarbonyl-, diC_{1-4}alkylaminocarbonyl-, benzyl, C_{3-12} cycloalkenyl-, a monocyclic, bicyclic or tricyclic aryl or heteroaryl ring, a hetero-monocyclic ring, a hetero-bicyclic ring system, and a spiro ring system of the formula (II):



(II)

wherein X_1 and X_2 are independently selected from the group consisting of NH, O, S and CH_2; and wherein said alkyl, cycloalkyl, alkenyl, C_{1-10}alkylamino-, C_{3-12}cycloalkylamino-, or benzyl of R_1 is optionally substituted with 1-3 substituents selected from the group consisting of halogen, hydroxy, C_{1-10} alkyl, C_{1-10} alkoxy, nitro, trifluoromethyl-, cyano, -$COOV_1$, -$C_{1-4}COOV_1$, cyanoC_{1-10}alkyl-, -C_{1-5}=OW_1, -$C_{1-5}NHS(=O)_2W_1$, -$C_{1-5}NHS(=O)W_1$, a 5-membered heteroaromaticC_{0-4}alkyl-, phenyl, benzyl, benzyloxy, said phenyl, benzyl, and benzyloxy optionally being substituted with 1-3 substituents selected from the group consisting of halogen, C_{1-10} alkyl-, C_{1-10} alkoxy-, and cyano; and wherein said C_{3-12} cycloalkyl, C_{3-12} cycloalkenyl, monocyclic, bicyclic or tricyclic aryl, heteroaryl ring, hetero-monocyclic ring, hetero-bicyclic ring system, or spiro ring system of the formula (II) is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C_{1-10} alkyl, C_{1-10} alkoxy, nitro, trifluoromethyl-, phenyl, benzyl, phenyloxy and benzyloxy, wherein said phenyl, benzyl, phenyloxy or benzyloxy is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C_{1-10} alkyl, C_{1-10} alkoxy, and cyano;

R_2 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{3-12} cycloalkyl and halogen, said alkyl or cycloalkyl optionally substituted with an oxo, amino, alkylamino or dialkylamino group;

or a pharmaceutically acceptable salt thereof or solvate thereof.

Claims 2-31 (Canceled)

32. (New) A compound of claim 1, wherein Q is a 6 membered heteroaromatic group containing 1-3 nitrogen atoms.

33. (New) A compound of claim 1, wherein W is selected from the group consisting of $-CH_2C{=}ONH_2$, $-C(NH)NH_2$, pyridylmethyl, cyclopentyl, cyclohexyl, furanylmethyl, $-C{=}OCH_3$, $-CH_2CH_2NHC{=}OCH_3$, $-SO_2CH_3$, $CH_2CH_2NHSO_2CH_3$, furanylcarbonyl-, methylpyrrolylcarbonyl-, diazolecarbonyl-, azolemethyl-, trifluoroethyl-, hydroxyethyl-, cyanomethyl-, oxo-oxazolemethyl-, and diazolemethyl-.

34. (New) A compound of claim 1, wherein ZR_1 is selected from the group consisting of cyclohexylethyl-, cyclohexylmethyl-, cyclopentylmethyl-, dimethylcyclohexylmethyl-, phenylethyl-, pyrrolyltrifluoroethyl-, thienyltrifluoroethyl-, pyridylethyl-, cyclopentyl-, cyclohexyl-, methoxycyclohexyl-, tetrahydropyranyl-, propylpiperidinyl-, indolylmethyl-, pyrazoylpentyl-, thiazolylethyl-, phenyltrifluoroethyl-, hydroxyhexyl-, methoxyhexyl-, isopropoxybutyl-, hexyl-, and oxocanylpropyl-.

35. (New) A compound of claim 1, wherein at least one of ZR_1 or W is selected from the group consisting of CH2COOV$_1$, tetrazolylmethyl-, cyanomethyl-, NH_2SO_2methyl-, NH_2SOmethyl-, aminocarbonylmethyl-, C_{1-4}alkylaminocarbonylmethyl-, and diC_{1-4}alkylaminocarbonylmethyl-.

36. (New) A compound of claim 1, wherein ZR_1 is 3,3 diphenylpropyl optionally substituted at the 3 carbon of the propyl with -COOV$_1$, tetrazolylC_{0-4}alkyl-, cyano-, aminocarbonyl-, C_{1-4}alkylaminocarbonyl-, or diC_{1-4}alkylaminocarbonyl-.

37. (New) A pharmaceutical composition comprising a compound of claim 1 and at least one pharmaceutically acceptable excipient.

38. (New) A method of treating pain comprising administering to a patient in need thereof, an

effective amount of an analegsic compound according to claim 1.

39. (New) A method of modulating a pharmacological response from the ORL1 receptor comprising administering to a patient in need thereof, an effective amount of a compound according to claim 1.

40. (New) A method of modulating a pharmacological response from an opioid receptor comprising administering to a patient in need thereof, an effective amount of a compound according to claim 1.